In this study, M. hominis in a large number (≥ 104-105 color changing units -CCU- /ml) in the vagina and cervix were detected most often in women with salpingitis at laparoscopy. However,

the significance of this mycoplasma, especially when associated with BV, can be difficult to assess when several microorganisms are present [3, 5]. Otherwise, M. hominis has been linked to a variety of extragenital infections, such as septicaemia, septic arthritis, wound infection, brain and perirenal abscesses, mediastinistis and other infections in immunocompromised patients [5]. Any assessment of the pathogenic potential of M. hominis is complicated by the high degree of genomic and antigenic heterogeneity observed within

the species. A few molecular typing methods have been developed for M. hominis. Pulse-field gel electrophoresis (PFGE) [6, 7], restriction fragment length polymorphism (RFLP) analysis [8], amplified fragment length MDV3100 chemical structure polymorphism (AFLP) GSK1120212 concentration [9] and random amplified polymorphic DNA (RADP) [10] have been used to study the genetic diversity of this species. However, these methods are time-consuming, require a relatively large amount of biological material, may be difficult to reproduce and standardise between laboratories and generate results that are difficult to interpret. Other molecular typing methods based on sequence analyses of the p75, p120’ and vaa genes have been developed [11–13]. An MLST approach based on the sequence analysis of six housekeeping genes and one gene encoding a membrane protein was conducted for 20 M. hominis isolates [14]. However, this method was used

to estimate the frequency of recombination in M. hominis, rather than for genotyping. Multiple locus variable-number tandem-repeat (VNTR) analysis (MLVA) is new genotyping method based on the variation in the copy numbers of tandem repeat (TR) sequences at different genomic loci among isolates. MLVA has been used successfully to subtype certain Mycoplasma species [15–19]. Using the recently described M. hominis PG21 genome sequence [20], we developed an automated MLVA Capmatinib clinical trial scheme, without a sequencing step, Edoxaban for M. hominis typing. This method was subsequently applied to a wide range of M. hominis clinical isolates from genital and extragenital infections collected between 1987 and 2009. We used MLVA to assess M. hominis genotypic diversity and characterise the pattern of human infections. Methods Ethics statement The present project is in compliance with the Helsinki Declaration (Ethical Principles for Medical Research Involving Human Subjects). The study was conducted in accordance with the guidelines of the “Direction de la Recherche Clinique et de l’Innovation”, the research board of Bordeaux University hospital, Bordeaux, France. All patient data were anonymously reported, with no possibility of connecting the isolates and specimens to individual patients.